Physical functioning is significantly diminished by intensive management of childhood posterior fossa brain tumors (PFTs) and correlates with survivors’ neurologic treatment burdens, suggests research presented at the 51st Annual ONS Congress in San Antonio, Texas. Read more: https://www.oncologynurseadvisor.com/reports/brain-tumors-functional-challenges-long-term-pediatric-pft/

In a study published in Cell Death & Disease, researchers led by Blanco identified a potential way to reduce relapse in medulloblastoma by targeting the tumor cells most likely to survive treatment and drive regrowth. Read more: https://www.news-medical.net/news/20260526/Scientists-target-root-of-relapse-in-aggressive-childhood-brain-tumors.aspx

For pediatric brain tumor survivors (PBTS), the necessity and challenge of sustaining meaningful friendships is more pronounced due to differences in social, emotional and neurocognitive abilities, areas collectively called psychosocial functioning. Read more: https://www.stjude.org/research/progress/2026/understanding-best-friendships-and-psychosocial-health-in-pediatric-brain-tumor-survivors.html

Blocking energy production pathways in an aggressive type of brain cancer in children could be a promising new therapeutic strategy, according to research in mice by Johns Hopkins Kimmel Cancer Center investigators. Read more: https://www.hopkinsmedicine.org/news/newsroom/news-releases/2026/04/blocking-energy-metabolism-may-help-treat-aggressive-pediatric-brain-tumor

Diagnosed with DIPG at age six, Lucas’ doctor Jacques Grill told Lucas’ parents, Cedric and Olesja, that he was unlikely to live very long. Instead of giving up hope, Cedric and Olesja flew Lucas to France to participate in a clinical trial called BIOMEDE, which tested new potential drugs against DIPG. Read more: https://www.upworthy.com/first-person-cured-of-dipg-ex1/

Now, results obtained by a study led by the University of Trento in collaboration with Bambino Gesù Children's Hospital in Rome may pave a path to an organoid that could be used to study two common, aggressive childhood brain cancers. Read more: https://medicalxpress.com/news/2026-03-avatar-pediatric-brain-cancer-reality.html

An international team led by researchers at Baylor College of Medicine, Texas Children’s Hospital, McGill University and University of Pittsburgh School of Medicine has discovered what drives the growth of a lethal pediatric brain tumor called Posterior Fossa Type A (PFA) ependymoma. Read more: https://www.eurekalert.org/news-releases/1121004

The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to AMXT 1501 to treat malignant gliomas , including a particularly aggressive childhood brain tumor called diffuse intrinsic pontine glioma (DIPG). Read more: https://rarecancernews.com/news/fda-grants-amxt-1501-orphan-drug-status-malignant-gliomas/

Immunotherapy has improved how doctors treat cancers all over the body, but so far it hasn’t been able to help children and young people with brain tumours. A discovery from researchers at the Cancer Research UK Cambridge Institute could finally change that. Read more: https://news.cancerresearchuk.org/2026/03/18/scientists-find-a-way-to-use-immunotherapy-to-treat-brain-tumours-in-children/

New research published in Nature finds that tumor cells within supratentorial ependymomas (SE)—an aggressive childhood brain cancer—cluster into distinct tumor cell populations. Read more: https://medicalxpress.com/news/2026-03-distinct-tumor-neighborhoods-treatments-aggressive.html